SELLAS Life Sciences Group, Inc. (SLS) has a negative trailing P/E of -27.4, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 1,472.7 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -3.65%, forward earnings yield 0.07%. PEG 0.46 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
Overall SharesGrow Score: 53/100 with 3/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -2.2 | -0.02 | 1.83 | 0.00 | - |
| 2017 | -0.7 | 0.02 | 8.48 | 0.00 | 3.85% |
| 2018 | -0.4 | 0.01 | 2.05 | 0.00 | 4.52% |
| 2019 | -0.4 | 0.00 | 1.25 | 0.00 | - |
| 2020 | -2.8 | 0.03 | 1.65 | 24.28 | - |
| 2021 | -4.1 | 0.11 | 4.21 | 11.26 | - |
| 2022 | -1.1 | -0.02 | 9.44 | 45.77 | - |
| 2023 | -0.8 | 0.02 | -3.69 | 0.00 | - |
| 2024 | -2.1 | 0.03 | 6.72 | 0.00 | - |
| 2025 | -15.3 | 0.31 | 5.80 | 0.00 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-394.12 | $0.00 | $-23.55M | - |
| 2017 | $-56.39 | $0.00 | $-23.75M | - |
| 2018 | $-11.76 | $0.00 | $-27.67M | - |
| 2019 | $-0.84 | $0.00 | $-19.29M | - |
| 2020 | $-2.11 | $1.9M | $-16.76M | -881.9% |
| 2021 | $-1.34 | $7.6M | $-20.7M | -272.4% |
| 2022 | $-2.13 | $1M | $-41.3M | -4130.1% |
| 2023 | $-0.15 | $0.00 | $-37.34M | - |
| 2024 | $-0.05 | $0.00 | $-30.88M | - |
| 2025 | $-0.25 | $0.00 | $-26.86M | - |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-0.28 | $-0.30 – $-0.27 | $36.13M | $34.95M – $37.32M | 2 |
| 2027 | $-0.18 | $-0.25 – $-0.07 | $45.74M | $44.25M – $47.24M | 3 |
| 2028 | $0.00 | $-0.25 – $0.30 | $123.63M | $119.59M – $127.67M | 3 |
| 2029 | $1.85 | $1.77 – $1.93 | $321.38M | $310.87M – $331.89M | 1 |
| 2030 | $3.65 | $3.49 – $3.81 | $575.93M | $557.1M – $594.77M | 1 |
